10-Q: Genprex Reports Third Quarter 2024 Results, Prioritizes Clinical Programs

Genprex, Inc. reports a net loss of $4.3 million for the third quarter of 2024, while focusing on its key clinical trials and strategic alternatives.

Summary

• Genprex, Inc. reported a net loss of $4.3 million for the three months ended September 30, 2024, compared to a net loss of $7.7 million for the same period in 2023.
• The company's research and development expenses decreased to $2.7 million in Q3 2024 from $4.6 million in Q3 2023, primarily due to changes in contract manufacturing and expense reduction strategies.
• General and administrative expenses also decreased to $1.5 million in Q3 2024 from $3.1 million in Q3 2023, due to reduced travel, professional services, and headcount.
• For the nine months ended September 30, 2024, the net loss was $16.7 million, compared to $24.9 million for the same period in 2023.
• The company's cash and cash equivalents stood at $1.4 million as of September 30, 2024.
• Genprex is prioritizing its Acclaim-1 and Acclaim-3 clinical trials and is considering strategic alternatives for its diabetes program, including a potential spin-out into a new subsidiary.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in clinical trials and cost-cutting measures, the company's weak financial position, material weaknesses in internal controls, and going concern warning raise significant concerns. The sentiment is therefore cautiously negative.

Positives

• The company has significantly reduced its net loss and operating expenses compared to the same period last year.
• The Acclaim-3 trial has shown early positive results with a patient experiencing a partial remission.
• The company is prioritizing its key clinical trials, Acclaim-1 and Acclaim-3, to focus resources.
• Genprex is exploring strategic alternatives for its diabetes program, which could unlock value.
• The company has received Fast Track Designation for the Acclaim-1 and Acclaim-3 treatment combinations from the FDA.

Negatives

• The company continues to operate at a loss and has an accumulated deficit of $150.4 million.
• Cash and cash equivalents are low at $1.4 million, raising concerns about the company's ability to fund operations.
• The company has ceased enrollment in the Acclaim-2 trial due to enrollment challenges and delays.
• There are material weaknesses in the company's internal controls over financial reporting.
• The company has a going concern warning due to recurring losses and the need for additional financing.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and the need for additional financing.
• There are material weaknesses in the company's internal controls over financial reporting, which could lead to errors in financial statements.
• The company may not be able to raise additional capital when needed on favorable terms, or at all.
• Clinical trials may experience delays, which could impact the company's timeline and financial resources.
• The company is dependent on third-party suppliers and manufacturers, which could lead to supply chain issues.
• There is no guarantee that the company's product candidates will receive regulatory approval or achieve commercial success.

Future Outlook

Genprex anticipates completing enrollment in the Phase 1 dose escalation portion of the Acclaim-3 study and starting the Phase 2 expansion portion in the second half of 2024. The company expects to complete the enrollment of the first 19 patients in the Phase 2a expansion portion of the Acclaim-1 study and conduct an interim analysis in the first half of 2025. Genprex is also considering a potential spin-out of its diabetes program into a new subsidiary by the end of 2024.

Management Comments

• The company believes that REQORSA may be providing clinical benefit based on the partial remission observed in the first patient treated in the Acclaim-3 trial.
• Management is actively engaged in remediation efforts to address the material weaknesses identified in the managements evaluation of internal controls and procedures.
• The company is considering various strategic alternatives and opportunities to enhance stockholder value, including evaluating ways to optimize its clinical and research programs and operational strategies.

Industry Context

Genprex is operating in the competitive biotechnology and pharmaceutical industry, focusing on gene therapy for cancer and diabetes. The company is facing challenges in clinical trial enrollment, which is common in this industry, and is prioritizing its resources to focus on its most promising programs. The potential spin-out of the diabetes program reflects a trend in the industry where companies are streamlining their operations to focus on core competencies.

Comparison to Industry Standards

• Genprex's cash burn rate is high, which is typical for clinical-stage biotech companies. For example, companies like Agenus Inc. and Cellectis SA, which are also in clinical stages, have similar cash burn rates.
• The company's decision to cease enrollment in the Acclaim-2 trial is not uncommon in the industry, as companies often need to prioritize resources and focus on the most promising programs. For example, companies like OncoSec Medical Incorporated have also had to make similar decisions.
• The partial remission observed in the Acclaim-3 trial is a positive sign, but it is still early data. Companies like Adaptimmune Therapeutics plc have also reported early positive results in their clinical trials, but these results need to be confirmed in larger studies.
• The potential spin-out of the diabetes program is a strategic move that is becoming more common in the industry, as companies look to unlock value and focus on core competencies. For example, companies like VBI Vaccines Inc. have also spun out assets to focus on their core business.
• Genprex's reliance on third-party manufacturers is also common in the industry, but it does expose the company to supply chain risks. Companies like Catalent, Inc. are major players in the contract manufacturing space, and companies like Genprex are dependent on their services.

Corporate Governance

Related Party Transactions

• There were no amounts incurred or due under the Assignment and Collaboration Agreement with Introgen Research Institute at September 30, 2024 and December 31, 2023.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need for additional financing.
• Employees may be affected by potential restructuring or changes in the company's strategic direction.
• Customers (patients) may benefit from the development of new therapies, but there is no guarantee of success.
• Suppliers and creditors face the risk of non-payment if the company's financial situation does not improve.

Next Steps

• Complete enrollment in the Phase 1 dose escalation portion of the Acclaim-3 clinical trial.
• Start the Phase 2 expansion portion of the Acclaim-3 clinical trial.
• Complete the enrollment of the first 19 patients in the Phase 2a expansion portion of the Acclaim-1 study.
• Conduct an interim analysis of the Acclaim-1 study.
• Continue preclinical work for potential other oncology candidates.
• Continue preclinical work and conduct clinical trials for the diabetes program.
• Potentially transfer the diabetes clinical development program and assets into a new subsidiary.
• Seek additional financing to fund operations.

Key Dates

Keywords

Genprex, gene therapy, cancer, diabetes, Reqorsa, clinical trials, Oncoprex Delivery System, TUSC2, Acclaim-1, Acclaim-3, GPX-002, financial results, biotechnology, pharmaceuticals